Fund moves
5.2%Stake
A Schedule 13D means the holder owns more than 5% and keeps the option to push for changes: board seats, a sale, buybacks. It must be filed within 5 business days.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
AZTR · NYSE · Pharmaceutical Preparations
Azitra (AZTR) · oqro.io/stocks/AZTR · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
No open-market purchase by an insider of Azitra was filed in the last 90 days. The latest on record was on Mar 29, 2024.
Since 2023, Azitra insiders reported 16 open-market purchases and 6 sales on Forms 4 and 5, with purchases in 2 different years, most recently 2024.
No open-market sale by an insider of Azitra (AZTR) was filed with the SEC in the last 90 days.
No trade in Azitra (AZTR) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
$0.5168−0.0146 (−2.75%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
−83.8% (−$2.67) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $3.19 on Nov 20, 2025 to $0.5168 on Nov 20, 2026 (−83.8%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Branford, Ct.
Last 12 months
−83.8%
Market value
$3.8M
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 306K shares sold short (4.2% of shares outstanding), +172.3% vs the previous count, 1.0 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Revenue, fiscal 2025
$0
−100.0% vs the year before
Net income, fiscal 2025
−$11M
A loss for the year
Shares outstanding
6.06M
As of Nov 12, 2026
Reverse split 1-for-10 took effect Oct 26, 2026. Calendar
Fund moves
A Schedule 13D means the holder owns more than 5% and keeps the option to push for changes: board seats, a sale, buybacks. It must be filed within 5 business days.
Fund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
On the public record for Azitra over the 12 months to Nov 17, 2026: 1 clinical trial.
Insiders of Azitra reported 16 open-market purchases and 6 sales since 2023; purchases in 2 different years, most recently 2024.
| Year | Bought | Sold |
|---|---|---|
| 2024 | $115K4×4 trades | — |
| 2023 | $6M12×12 trades | —6×6 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Notice of delisting or failure to meet listing rules
8-K on sec.govNotice of delisting or failure to meet listing rules
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
Revenue
—
Year earlier: $0
Free cash flow, last 12 months
−$11.6M
This quarter −$2.92M, a year earlier −$2.45M
Net debt
—
Debt —, cash $3.75M, at Sep 30, 2026
Net income, last 12 months
−$12.5M
Operating loss: profit did not cover interest
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 12, 2026.
Revenue and earnings history, 4 fiscal yearsEarnings dates and the stock's moves
Latest annual report filed Feb 27, 2026, compared with the one filed Feb 24, 2025. Read the filing
As of the date of this report, there are no legal proceedings to which we or our properties are subject. We may be involved, from time to time, in legal proceedings and claims arising in the ordinary course of its business. Such matters are subject to many uncertainties and outcomes and are not predictable with assurance.
Source: SEC EDGAR, Form 10-K filed Feb 27, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 6,000 words.
We are focused on developing innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. We have built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for unique therapeutic characteristics. The platform is augmented by an artificial intelligence and machine learning technology, which can enable the transformation of previously genetically intractable strains. Our initial focus is on the development of genetically engineered strains of Staphylococcus epidermidis, or S. epidermidis, which we consider to be an optimal therapeutic candidate species for engineering of dermatologic therapies.
Who holds it
Things to keep in mind
And 2 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Feb 27, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Recent moves
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Off-exchange trading: about 2.5 million shares a week traded away from the exchanges over the latest 4 published weeks, 158 thousand of them on ATS. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: IBKR ATS (36.5%), BOATS (21.2%), LEVEL ATS (8.4%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others.
0 active phase 3 trials and 1 active phase 2 trial led by this company, mostly in egfr inhibitor-associated rash. The ones with the nearest registered primary completion date still ahead:
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.